Provided by Tiger Fintech (Singapore) Pte. Ltd.

Enanta Pharmaceuticals

6.30
+0.20003.28%
Post-market: 6.300.00000.00%16:08 EDT
Volume:278.22K
Turnover:1.72M
Market Cap:134.40M
PE:-1.27
High:6.32
Open:5.97
Low:5.93
Close:6.10
Loading ...

Company Profile

Company Name:
Enanta Pharmaceuticals
Exchange:
NASDAQ
Establishment Date:
1995
Employees:
131
Office Location:
4 Kingsbury Avenue,Watertown,Massachusetts,United States
Zip Code:
02472
Fax:
617 607 0530
Introduction:
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.

Directors

Name
Position
Bruce L. A. Carter
Non-Executive Chairman of the Board
Jay R. Luly
President and Chief Executive Officer and Director
Kristine Peterson
Director
Lesley Russell
Director
Mark G. Foletta
Director
Terry Vance
Director
Yujiro S. Hata
Director

Shareholders

Name
Position
Jay R. Luly
President and Chief Executive Officer and Director
Brendan Luu
Chief Business Officer
Nathaniel S. Gardiner
Chief Legal Officer and Corporate Secretary
Paul J. Mellett
Chief Financial and Administrative Officer
Scott T. Rottinghaus
Chief Medical Officer
Tara L. Kieffer
Chief Product Strategy Officer
Yat Sun Or
Chief Scientific Officer